All In Biotech

Drug Trial Radar · NCT02436096

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 519 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

519

Actual

Start

Apr 2015

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Lead sponsor
Tonix Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202 study provided evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology. The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.

Conditions

  • Fibromyalgia
  • Myofascial Pain Syndromes
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Nervous System Diseases
  • Neuromuscular Diseases
  • Rheumatic Diseases

Interventions

  • TNX-102 SL Tablet, 2.8mgDrug

    Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

  • Placebo SL TabletDrug

    Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With ≥30% Pain ImprovementTime frame: Day 1, Week 12

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Brandon, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Lakeland, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Evansville, Indiana

  • Site not named

    North Dartmouth, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Jackson, Mississippi

  • Site not named

    Williamsville, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Middleburg Heights, Ohio

  • Site not named

    Medford, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Allentown, Pennsylvania

  • Site not named

    Warwick, Rhode Island

  • Site not named

    Greer, South Carolina

  • Site not named

    Mt. Pleasant, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Norfolk, Virginia

  • Site not named

    Bellevue, Washington

  • Site not named

    Seattle, Washington

  • Site not named

    Kenosha, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.